SARCOPENIA TREATMENT MARKET ANALYSIS

Regional Analysis

Sarcopenia Treatment Market Regional Analysis

North America is expected to hold a dominant position in the sarcopenia treatment market, owing to presence of developed healthcare facilities and infrastructure in countries such as the U.S, and Canada. Moreover, the demand for sarcopenia treatment has increased in the region due to high focus on healthcare by the government, technological advancements are likely to fuel growth of the sarcopenia treatment market during the forecast period.

Europe is expected to be the second largest sarcopenia treatment market over the forecast period. For instance, in February 2019, Biophytis SA, a Paris (France) based company focused on development of novel therapeutics for age-related diseases, announced three oral and poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research (ICFSR). In this conference, the company presented the details of its lead clinical drug candidate, Sarconeos (BIO 101), that included its history and unique mechanism that targets the MAS receptor for preservation of muscle function in muscle wasting disorder. In addition, the company also presented the clinical trial design of its ongoing SARA Phase 2 study of Sarconeos to treat sarcopenia.